Related Experiment Video
Updated: Mar 27, 2026
The Application of Open Searching-based Approaches for the Identification of Acinetobacter baumannii O-linked Glycopeptides
Published on: November 2, 2021
A Phage Endolysin-Derived Binding Protein Targeting the LysM Motif Enables Highly Specific Identification of
Shukho Kim1,2,3, Yoon-Jung Choi1,3, Md Shohel Rana2
1Department of Microbiology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Abstract:
Acinetobacter baumannii, a member of the A. baumannii-calcoaceticus complex (ABC), is a major cause of hospital-acquired infections. Differentiating A. baumannii from other ABC species remains challenging. In this study, we developed a novel diagnostic platform utilizing the cell wall-binding domain (CBD) of an endolysin from A. baumannii phage Φ1656-2. The CBD was expressed as a recombinant protein (AbCD) and conjugated to epoxy magnetic beads (eMB) to form the AbCD-eMB complex. This complex enabled rapid, selective capture of A. baumannii within 1 h, with recovery rates of 72.5% in buffer and 55.7% in clinical sputum specimens. Specificity was confirmed against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and non-A. baumannii strains, with no significant cross-reactivity. The detection limit was approximately 3.4 × 103 CFU/mL. All captured clinical isolates harbored the blaOXA-51-like gene. Functional analysis and molecular docking identified the Lysin motif (LysM)-containing peptidoglycan-binding domain as the bacterial receptor for AbCD. The AbCD-eMB complex remained stable at 4 °C for up to one month. This study demonstrates that the AbCD-eMB platform provides a culture-independent, rapid, and highly specific diagnostic approach for A. baumannii, offering strong potential for clinical diagnostics and point-of-care testing.
Insights
A new diagnostic platform rapidly captures Acinetobacter baumannii using a phage endolysin
Area of Science:
- Microbiology
- Biotechnology
- Infectious Diseases
Background:
- Acinetobacter baumannii is a significant cause of hospital-acquired infections.
- Distinguishing A. baumannii from related species is diagnostically challenging.
- Current diagnostic methods can be time-consuming and complex.
Purpose of the Study:
- To develop a novel, rapid, and specific diagnostic platform for Acinetobacter baumannii.
- To utilize the cell wall-binding domain of an endolysin for bacterial capture.
- To enable culture-independent detection of A. baumannii.
Main Methods:
- Engineered a recombinant cell wall-binding domain (AbCD) from Acinetobacter baumannii phage Φ1656-2 endolysin.
- Conjugated AbCD to epoxy magnetic beads (AbCD-eMB) for selective capture.
- Validated specificity against various bacterial species and tested in clinical sputum specimens.
Main Results:
- The AbCD-eMB complex rapidly captured Acinetobacter baumannii within 1 hour.
- Achieved recovery rates of 72.5% in buffer and 55.7% in sputum specimens.
- Demonstrated high specificity with no cross-reactivity against other common pathogens; detection limit ~3.4 × 10^3 CFU/mL.
Conclusions:
- The AbCD-eMB platform offers a rapid, culture-independent, and highly specific method for Acinetobacter baumannii detection.
- This approach has significant potential for clinical diagnostics and point-of-care testing.
- Identified the LysM-containing peptidoglycan-binding domain as the key bacterial receptor for AbCD.
More Related Videos
07:59Rapid and Specific Detection of Acinetobacter baumannii Infections Using a Recombinase Polymerase Amplification/Cas12a-based System
Published on: April 25, 2025
08:06The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
